The drug-resistant fungus Candidozyma auris (candida auris) is spreading rapidly across Europe, raising alarm in hospitals and intensive care units, including in Greece. Health experts warn that infections are difficult to control due to the pathogen’s ability to survive on surfaces and resist antifungal drugs and disinfectants.

Candidozyma auris thrives in warmer environments with high salt (unlike other candida species) and is thought to have emerged as a human pathogen due to global warming.

Europe Sees Sharp Increase

According to Matina Pagoni, vice president of the Federation of Hospital Doctors of Greece (OENGE), Candida auris is a hospital-acquired fungus and cases in Europe have surged by 60% in 2025. “We see it every year, but this year the increase is significant,” she told Greek television.

Between 2013 and 2023, 4,012 infections were recorded across EU and EEA member states. The five countries with the highest number of cases were:

  • Spain: 1,807 cases
  • Greece: 852 cases
  • Italy: 712 cases
  • Romania: 404 cases
  • Germany: 120 cases

This places Greece second in Europe for Candida auris infections, highlighting its vulnerability compared with other EU countries.

A Persistent and Resistant Threat

Candida auris poses a particular challenge in intensive care units (ICUs) and wards treating immunocompromised patients. The fungus can cause:

  • Bloodstream infections, spreading throughout the body
  • Wound infections
  • Urinary tract infections
  • Ear infections

Experts emphasize that hand hygiene remains the most effective preventive measure, recommending thorough washing before and after visiting hospitals.

Why It Matters

Candida auris is classified as a serious global health threat by health authorities due to its high resistance to treatment and ability to trigger outbreaks in healthcare facilities. Its rise in Greece and across Europe underscores the urgent need for stronger infection-control protocols and surveillance.